Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
Price : $35 *
At a glance
- Drugs Dovitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Jul 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 16 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.